Non-canonical cell death induced by p53

International Journal of Molecular Sciences

Volumn 17, Issue 12, 2016, Pages

  Ranjan, Atul ^a   Iwakuma, Tomoo ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Autophagy; Caspase independent apoptosis (CIA); Efferocytosis; Ferroptosis; Mitotic catastrophe; Necroptosis; Paraptosis; Pyroptosis

Indexed keywords

DOCETAXEL; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; PACLITAXEL; PHOSPHOLIPID HYDROPEROXIDE GLUTATHIONE PEROXIDASE; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P53; VINBLASTINE; VINCRISTINE;

APOPTOSIS; AUTOPHAGOSOME; AUTOPHAGY; CANCER CELL; CANCER THERAPY; CELL CYCLE ARREST; CELL DEATH; CELL PROLIFERATION; DNA FRAGMENTATION; HUMAN; IMMUNOSENESCENCE; MOLECULARLY TARGETED THERAPY; NECROPTOSIS; PYROPTOSIS; REVIEW; TUMOR SUPPRESSOR GENE; UPREGULATION; ANIMAL; GENETICS; METABOLISM; NECROSIS; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; AUTOPHAGY; CELL DEATH; HUMANS; NECROSIS; PYROPTOSIS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 85006168521     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17122068     Document Type: Review

References (157)

1. Vogt, C. Untersuchungen Uber Die Entwicklungsgeschichte der Geburtshelferkröte (Alytes Obstetricans); Jent und Gassmann: Solothurn, Switzerland, 1984.
2. Kroemer, G.; Galluzzi, L.; Vandenabeele, P.; Abrams, J.; Alnemri, E.S.; Baehrecke, E.H.; Blagosklonny, M.V.; El-Deiry, W.S.; Golstein, P.; Green, D.R. et al. Classification of cell death: Recommendations of the nomenclature committee on cell death 2009. Cell Death Differ. 2009, 16, 3–11.
3. Ellis, R.E.; Yuan, J.Y.; Horvitz, H.R. Mechanisms and functions of cell death. Annu. Rev. Cell Biol. 1991, 7, 663–698.
4. Jacobson, M.D.; Weil, M.; Raff, M.C. Programmed cell death in animal development. Cell 1997, 88, 347–354.
5. Kerr, J.F.; Wyllie, A.H.; Currie, A.R. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer 1972, 26, 239–257.
6. Elmore, S. Apoptosis: A review of programmed cell death. Toxicol. Pathol. 2007, 35, 495–516.
7. Wang, S.; El-Deiry, W.S. Trail and apoptosis induction by TNF-family death receptors. Oncogene 2003, 22, 8628–8633.
8. Wajant, H. The Fas signaling pathway: More than a paradigm. Science 2002, 296, 1635–1636.
9. Rossi, D.; Gaidano, G. Messengers of cell death: Apoptotic signaling in health and disease. Haematologica 2003, 88, 212–218.
10. Evans-Storms, R.B.; Cidlowski, J.A. Regulation of apoptosis by steroid hormones. J. Steroid Biochem. Mol. Biol. 1995, 53, 1–8.
11. Herbst, S.; Schaible, U.E.; Schneider, B.E. Interferon gamma activated macrophages kill mycobacteria by nitric oxide induced apoptosis. PLoS ONE 2011, 6, e19105.
12. Olivares-Zavaleta, N.; Carmody, A.; Messer, R.; Whitmire, W.M.; Caldwell, H.D. Chlamydia pneumoniae inhibits activated human T lymphocyte proliferation by the induction of apoptotic and pyroptotic pathways. J. Immunol. 2011, 186, 7120–7126.
13. Fan, X.Y.; Chen, X.Y.; Liu, Y.J.; Zhong, H.M.; Jiang, F.L.; Liu, Y. Oxidative stress-mediated intrinsic apoptosis in human promyelocytic leukemia HL-60 cells induced by organic arsenicals. Sci. Rep. 2016, 6, 29865.
14. Sano, R.; Reed, J.C. ER stress-induced cell death mechanisms. Biochim. Biophys. Acta 2013, 1833, 3460–3470.
15. Fulda, S.; Debatin, K.M. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006, 25, 4798–4811.
16. Igney, F.H.; Krammer, P.H. Death and anti-death: Tumour resistance to apoptosis. Nat. Rev. Cancer 2002, 2, 277–288.
17. McIlwain, D.R.; Berger, T.; Mak, T.W. Caspase functions in cell death and disease. Cold Spring Harb. Perspect. Biol. 2013, 5, a008656.
18. Duprez, L.; Wirawan, E.; Vanden Berghe, T.; Vandenabeele, P. Major cell death pathways at a glance. Microbes Infect. 2009, 11, 1050–1062.
19. Okada, H.; Mak, T.W. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat. Rev. Cancer 2004, 4, 592–603.
20. Diederich, M.; Cerella, C. Non-canonical programmed cell death mechanisms triggered by natural compounds. Semin. Cancer Biol. 2016, 40–41, 4–34.
21. Parrales, A.; Iwakuma, T. Targeting oncogenic mutant p53 for cancer therapy. Front. Oncol. 2015, 5, 288.
22. Iwakuma, T.; Lozano, G. Crippling p53 activities via knock-in mutations in mouse models. Oncogene 2007, 26, 2177–2184.
23. Lane, D.; Levine, A. p53 research: The past thirty years and the next thirty years. Cold Spring Harb. Perspect. Biol. 2010, 2, a000893.
24. Huang, D.C.; Strasser, A. BH3-only proteins-essential initiators of apoptotic cell death. Cell 2000, 103, 839–842.
25. Galluzzi, L.; Morselli, E.; Kepp, O.; Tajeddine, N.; Kroemer, G. Targeting p53 to mitochondria for cancer therapy. Cell Cycle 2008, 7, 1949–1955.
26. El-Deiry, W.S. The role of p53 in chemosensitivity and radiosensitivity. Oncogene 2003, 22, 7486–7495.
27. Kumar, A.; Rothman, J.H. Cell death: Hook, line and linker. Curr. Biol. 2007, 17, R286–R289.
28. Ekert, P.G.; Read, S.H.; Silke, J.; Marsden, V.S.; Kaufmann, H.; Hawkins, C.J.; Gerl, R.; Kumar, S.; Vaux, D.L. Apaf-1 and caspase-9 accelerate apoptosis, but do not determine whether factor-deprived or drug-treated cells die. J. Cell Biol. 2004, 165, 835–842.
29. Padhye, S.; Dandawate, P.; Yusufi, M.; Ahmad, A.; Sarkar, F.H. Perspectives on medicinal properties of plumbagin and its analogs. Med. Res. Rev. 2012, 32, 1131–1158.
30. Wang, J.; Guo, W.; Zhou, H.; Luo, N.; Nie, C.; Zhao, X.; Yuan, Z.; Liu, X.; Wei, Y. Mitochondrial p53 phosphorylation induces Bak-mediated and caspase-independent cell death. Oncotarget 2015, 6, 17192–17205.
31. Ahn, H.J.; Kim, Y.S.; Kim, J.U.; Han, S.M.; Shin, J.W.; Yang, H.O. Mechanism of taxol-induced apoptosis in human SKOV3 ovarian carcinoma cells. J. Cell Biochem. 2004, 91, 1043–1052.
32. Broker, L.E.; Huisman, C.; Span, S.W.; Rodriguez, J.A.; Kruyt, F.A.; Giaccone, G. Cathepsin B mediates caspase-independent cell death induced by microtubule stabilizing agents in non-small cell lung cancer cells. Cancer Res. 2004, 64, 27–30.
33. Susin, S.A.; Lorenzo, H.K.; Zamzami, N.; Marzo, I.; Snow, B.E.; Brothers, G.M.; Mangion, J.; Jacotot, E.; Costantini, P.; Loeffler, M. et al. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 1999, 397, 441–446.
34. Li, L.Y.; Luo, X.; Wang, X. Endonuclease G is an apoptotic dnase when released from mitochondria. Nature 2001, 412, 95–99.
35. Van Loo, G.; Schotte, P.; van Gurp, M.; Demol, H.; Hoorelbeke, B.; Gevaert, K.; Rodriguez, I.; Ruiz-Carrillo, A.; Vandekerckhove, J.; Declercq, W. et al. Endonuclease G: A mitochondrial protein released in apoptosis and involved in caspase-independent DNA degradation. Cell Death Differ. 2001, 8, 1136–1142.
36. Miramar, M.D.; Costantini, P.; Ravagnan, L.; Saraiva, L.M.; Haouzi, D.; Brothers, G.; Penninger, J.M.; Peleato, M.L.; Kroemer, G.; Susin, S.A. NADH oxidase activity of mitochondrial apoptosis-inducing factor. J. Biol. Chem. 2001, 276, 16391–16398.
37. Ye, H.; Cande, C.; Stephanou, N.C.; Jiang, S.; Gurbuxani, S.; Larochette, N.; Daugas, E.; Garrido, C.; Kroemer, G.; Wu, H. DNA binding is required for the apoptogenic action of apoptosis inducing factor. Nat. Struct. Biol. 2002, 9, 680–684.
38. Loeffler, M.; Daugas, E.; Susin, S.A.; Zamzami, N.; Metivier, D.; Nieminen, A.L.; Brothers, G.; Penninger, J.M.; Kroemer, G. Dominant cell death induction by extramitochondrially targeted apoptosis-inducing factor. FASEB J. 2001, 15, 758–767.
39. Cregan, S.P.; Fortin, A.; MacLaurin, J.G.; Callaghan, S.M.; Cecconi, F.; Yu, S.W.; Dawson, T.M.; Dawson, V.L.; Park, D.S.; Kroemer, G. et al. Apoptosis-inducing factor is involved in the regulation of caspase-independent neuronal cell death. J. Cell Biol. 2002, 158, 507–517.
40. Braun, J.S.; Novak, R.; Murray, P.J.; Eischen, C.M.; Susin, S.A.; Kroemer, G.; Halle, A.; Weber, J.R.; Tuomanen, E.I.; Cleveland, J.L. Apoptosis-inducing factor mediates microglial and neuronal apoptosis caused by pneumococcus. J. Infect. Dis. 2001, 184, 1300–1309.
41. Leu, J.I.; Dumont, P.; Hafey, M.; Murphy, M.E.; George, D.L. Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat. Cell Biol. 2004, 6, 443–450.
42. Vaseva, A.V.; Moll, U.M. The mitochondrial p53 pathway. Biochim. Biophys. Acta 2009, 1787, 414–420.
43. Miyashita, T.; Reed, J.C. Tumor suppressor p53 is a direct transcriptional activator of the human Bax gene. Cell 1995, 80, 293–299.
44. Wu, Y.; Mehew, J.W.; Heckman, C.A.; Arcinas, M.; Boxer, L.M. Negative regulation of Bcl-2 expression by p53 in hematopoietic cells. Oncogene 2001, 20, 240–251.
45. Stambolsky, P.; Weisz, L.; Shats, I.; Klein, Y.; Goldfinger, N.; Oren, M.; Rotter, V. Regulation of AIF expression by p53. Cell Death Differ. 2006, 13, 2140–2149.
46. Dixon, S.J.; Lemberg, K.M.; Lamprecht, M.R.; Skouta, R.; Zaitsev, E.M.; Gleason, C.E.; Patel, D.N.; Bauer, A.J.; Cantley, A.M.; Yang, W.S. et al. Ferroptosis: An iron-dependent form of nonapoptotic cell death. Cell 2012, 149, 1060–1072.
47. Skouta, R.; Dixon, S.J.; Wang, J.; Dunn, D.E.; Orman, M.; Shimada, K.; Rosenberg, P.A.; Lo, D.C.; Weinberg, J.M.; Linkermann, A. et al. Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models. J. Am. Chem. Soc. 2014, 136, 4551–4556.
48. Linkermann, A.; Skouta, R.; Himmerkus, N.; Mulay, S.R.; Dewitz, C.; de Zen, F.; Prokai, A.; Zuchtriegel, G.; Krombach, F.; Welz, P.S. et al. Synchronized renal tubular cell death involves ferroptosis. Proc. Natl. Acad. Sci. USA 2014, 111, 16836–16841.
49. Friedmann Angeli, J.P.; Schneider, M.; Proneth, B.; Tyurina, Y.Y.; Tyurin, V.A.; Hammond, V.J.; Herbach, N.; Aichler, M.; Walch, A.; Eggenhofer, E. et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat. Cell Biol. 2014, 16, 1180–1191.
50. Gao, M.; Monian, P.; Quadri, N.; Ramasamy, R.; Jiang, X. Glutaminolysis and transferrin regulate ferroptosis. Mol. Cell 2015, 59, 298–308.
51. Cao, J.Y.; Dixon, S.J. Mechanisms of ferroptosis. Cell. Mol. Life Sci. 2016, 73, 2195–2209.
52. Xie, Y.; Hou, W.; Song, X.; Yu, Y.; Huang, J.; Sun, X.; Kang, R.; Tang, D. Ferroptosis: Process and function. Cell Death Differ. 2016, 23, 369–379.
53. Yang, W.S.; SriRamaratnam, R.; Welsch, M.E.; Shimada, K.; Skouta, R.; Viswanathan, V.S.; Cheah, J.H.; Clemons, P.A.; Shamji, A.F.; Clish, C.B. et al. Regulation of ferroptotic cancer cell death by Gpx4. Cell 2014, 156, 317–331.
54. Dolma, S.; Lessnick, S.L.; Hahn, W.C.; Stockwell, B.R. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell 2003, 3, 285–296.
55. Yagoda, N.; von Rechenberg, M.; Zaganjor, E.; Bauer, A.J.; Yang, W.S.; Fridman, D.J.; Wolpaw, A.J.; Smukste, I.; Peltier, J.M.; Boniface, J.J. et al. RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature 2007, 447, 864–868.
56. Yang, W.S.; Stockwell, B.R. Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-Ras-harboring cancer cells. Chem. Biol. 2008, 15, 234–245.
57. Jiang, L.; Kon, N.; Li, T.; Wang, S.J.; Su, T.; Hibshoosh, H.; Baer, R.; Gu, W. Ferroptosis as a p53-mediated activity during tumour suppression. Nature 2015, 520, 57–62.
58. Wang, S.J.; Ou, Y.; Jiang, L.; Gu, W. Ferroptosis: A missing puzzle piece in the p53 blueprint? Mol. Cell. Oncol. 2016, 3, e1046581.
59. Galluzzi, L.; Bravo-San Pedro, J.M.; Kroemer, G. Ferroptosis in p53-dependent oncosuppression and organismal homeostasis. Cell Death Differ. 2015, 22, 1237–1238.
60. Proskuryakov, S.Y.; Konoplyannikov, A.G.; Gabai, V.L. Necrosis: A specific form of programmed cell death? Exp. Cell Res. 2003, 283, 1–16.
61. Edinger, A.L.; Thompson, C.B. Death by design: Apoptosis, necrosis and autophagy. Curr. Opin. Cell Biol. 2004, 16, 663–669.
62. Majno, G.; Joris, I. Apoptosis, oncosis, and necrosis. An overview of cell death. Am. J. Pathol. 1995, 146, 3–15.
63. Linkermann, A.; Green, D.R. Necroptosis. N. Engl. J. Med. 2014, 370, 455–465.
64. Galluzzi, L.; Kroemer, G. Necroptosis: A specialized pathway of programmed necrosis. Cell 2008, 135, 1161–1163.
65. Laster, S.M.; Wood, J.G.; Gooding, L.R. Tumor necrosis factor can induce both apoptic and necrotic forms of cell lysis. J. Immunol. 1988, 141, 2629–2634.
66. Matsumura, H.; Shimizu, Y.; Ohsawa, Y.; Kawahara, A.; Uchiyama, Y.; Nagata, S. Necrotic death pathway in Fas receptor signaling. J. Cell Biol. 2000, 151, 1247–1256.
67. Holler, N.; Zaru, R.; Micheau, O.; Thome, M.; Attinger, A.; Valitutti, S.; Bodmer, J.L.; Schneider, P.; Seed, B.; Tschopp, J. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase rip as effector molecule. Nat. Immunol. 2000, 1, 489–495.
68. Newton, K.; Dugger, D.L.; Wickliffe, K.E.; Kapoor, N.; de Almagro, M.C.; Vucic, D.; Komuves, L.; Ferrando, R.E.; French, D.M.; Webster, J. et al. Activity of protein kinase RIPK3 determines whether cells die by necroptosis or apoptosis. Science 2014, 343, 1357–1360.
69. Moriwaki, K.; Chan, F.K. Necrosis-dependent and independent signaling of the RIP kinases in inflammation. Cytokine Growth Factor Rev. 2014, 25, 167–174.
70. Sun, L.; Wang, H.; Wang, Z.; He, S.; Chen, S.; Liao, D.; Wang, L.; Yan, J.; Liu, W.; Lei, X. et al. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell 2012, 148, 213–227.
71. Wang, H.; Sun, L.; Su, L.; Rizo, J.; Liu, L.; Wang, L.F.; Wang, F.S.; Wang, X. Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption upon phosphorylation by RIP3. Mol. Cell 2014, 54, 133–146.
72. Moujalled, D.M.; Cook, W.D.; Okamoto, T.; Murphy, J.; Lawlor, K.E.; Vince, J.E.; Vaux, D.L. TNF can activate RIPK3 and cause programmed necrosis in the absence of RIPK1. Cell Death Dis. 2013, 4, e465.
73. Tu, H.C.; Ren, D.; Wang, G.X.; Chen, D.Y.; Westergard, T.D.; Kim, H.; Sasagawa, S.; Hsieh, J.J.; Cheng, E.H. The p53-cathepsin axis cooperates with Ros to activate programmed necrotic death upon DNA damage. Proc. Natl. Acad. Sci. USA 2009, 106, 1093–1098.
74. Vaseva, A.V.; Marchenko, N.D.; Ji, K.; Tsirka, S.E.; Holzmann, S.; Moll, U.M. p53 opens the mitochondrial permeability transition pore to trigger necrosis. Cell 2012, 149, 1536–1548.
75. Wang, K.; Liu, F.; Liu, C.Y.; An, T.; Zhang, J.; Zhou, L.Y.; Wang, M.; Dong, Y.H.; Li, N.; Gao, J.N. et al. The long noncoding RNA NRF regulates programmed necrosis and myocardial injury during ischemia and reperfusion by targeting miR-873. Cell Death Differ. 2016, 23, 1394–1405.
76. Glick, D.; Barth, S.; Macleod, K.F. Autophagy: Cellular and molecular mechanisms. J. Pathol. 2010, 221, 3–12.
77. Mizushima, N. Autophagy: Process and function. Genes Dev. 2007, 21, 2861–2873.
78. Mortimore, G.E.; Poso, A.R.; Kadowaki, M.; Wert, J.J., Jr. Multiphasic control of hepatic protein degradation by regulatory amino acids. General features and hormonal modulation. J. Biol. Chem. 1987, 262, 16322–16327.
79. Cao, Y.; Klionsky, D.J. Physiological functions of ATG6/Beclin 1: A unique autophagy-related protein. Cell Res. 2007, 17, 839–849.
80. Ganley, I.G.; Lam du, H.; Wang, J.; Ding, X.; Chen, S.; Jiang, X. ULK1.ATG13.FIP200 complex mediates mTOR signaling and is essential for autophagy. J. Biol. Chem. 2009, 284, 12297–12305.
81. Jung, C.H.; Jun, C.B.; Ro, S.H.; Kim, Y.M.; Otto, N.M.; Cao, J.; Kundu, M.; Kim, D.H. ULK-ATG13-FIP200 complexes mediate mTOR signaling to the autophagy machinery. Mol. Biol. Cell 2009, 20, 1992–2003.
82. Jung, C.H.; Ro, S.H.; Cao, J.; Otto, N.M.; Kim, D.H. mTOR regulation of autophagy. FEBS Lett. 2010, 584, 1287–1295.
83. Shimizu, S.; Kanaseki, T.; Mizushima, N.; Mizuta, T.; Arakawa-Kobayashi, S.; Thompson, C.B.; Tsujimoto, Y. Role of Bcl-2 family proteins in a non-apoptotic programmed cell death dependent on autophagy genes. Nat. Cell Biol. 2004, 6, 1221–1228.
84. Tang, H.; Sebti, S.; Titone, R.; Zhou, Y.; Isidoro, C.; Ross, T.S.; Hibshoosh, H.; Xiao, G.; Packer, M.; Xie, Y. et al. Decreased BECN1 mRNA expression in human breast cancer is associated with estrogen receptor-negative subtypes and poor prognosis. EBioMedicine 2015, 2, 255–263.
85. Liang, X.H.; Jackson, S.; Seaman, M.; Brown, K.; Kempkes, B.; Hibshoosh, H.; Levine, B. Induction of autophagy and inhibition of tumorigenesis by Beclin 1. Nature 1999, 402, 672–676.
86. Shi, Y.H.; Ding, Z.B.; Zhou, J.; Qiu, S.J.; Fan, J. Prognostic significance of Beclin 1-dependent apoptotic activity in hepatocellular carcinoma. Autophagy 2009, 5, 380–382.
87. Maiuri, M.C.; Galluzzi, L.; Morselli, E.; Kepp, O.; Malik, S.A.; Kroemer, G. Autophagy regulation by p53. Curr. Opin. Cell Biol. 2010, 22, 181–185.
88. Feng, Z.; Zhang, H.; Levine, A.J.; Jin, S. The coordinate regulation of the p53 and mTOR pathways in cells. Proc. Natl. Acad. Sci. USA 2005, 102, 8204–8209.
89. Feng, Z.; Hu, W.; de Stanchina, E.; Teresky, A.K.; Jin, S.; Lowe, S.; Levine, A.J. The regulation of AMPK β1, TSC2, and pten expression by p53: Stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways. Cancer Res. 2007, 67, 3043–3053.
90. Budanov, A.V.; Karin, M. p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling. Cell 2008, 134, 451–460.
91. Criollo, A.; Dessen, P.; Kroemer, G. Dram: A phylogenetically ancient regulator of autophagy. Cell Cycle 2009, 8, 2319–2320.
92. Mrschtik, M.; O’Prey, J.; Lao, L.Y.; Long, J.S.; Beaumatin, F.; Strachan, D.; O’Prey, M.; Skommer, J.; Ryan, K.M. Dram-3 modulates autophagy and promotes cell survival in the absence of glucose. Cell Death Differ 2015, 22, 1714–1726.
93. Crighton, D.; Wilkinson, S.; O’Prey, J.; Syed, N.; Smith, P.; Harrison, P.R.; Gasco, M.; Garrone, O.; Crook, T.; Ryan, K.M. Dram, a p53-induced modulator of autophagy, is critical for apoptosis. Cell 2006, 126, 121–134.
94. Wang, E.Y.; Gang, H.; Aviv, Y.; Dhingra, R.; Margulets, V.; Kirshenbaum, L.A. p53 mediates autophagy and cell death by a mechanism contingent on Bnip3. Hypertension 2013, 62, 70–77.
95. Yee, K.S.; Wilkinson, S.; James, J.; Ryan, K.M.; Vousden, K.H. PUMA- and Bax-induced autophagy contributes to apoptosis. Cell Death Differ. 2009, 16, 1135–1145.
96. Quinsay, M.N.; Thomas, R.L.; Lee, Y.; Gustafsson, A.B. BNIP3-mediated mitochondrial autophagy is independent of the mitochondrial permeability transition pore. Autophagy 2010, 6, 855–862.
97. Maiuri, M.C.; Criollo, A.; Tasdemir, E.; Vicencio, J.M.; Tajeddine, N.; Hickman, J.A.; Geneste, O.; Kroemer, G. BH3-only proteins and BH3 mimetics induce autophagy by competitively disrupting the interaction between Beclin 1 and Bcl-2/Bcl-xl. Autophagy 2007, 3, 374–376.
98. Tripathi, R.; Ash, D.; Shaha, C. Beclin-1-p53 interaction is crucial for cell fate determination in embryonal carcinoma cells. J. Cell. Mol. Med. 2014, 18, 2275–2286.
99. Tasdemir, E.; Maiuri, M.C.; Galluzzi, L.; Vitale, I.; Djavaheri-Mergny, M.; D’Amelio, M.; Criollo, A.; Morselli, E.; Zhu, C.; Harper, F. et al. Regulation of autophagy by cytoplasmic p53. Nat. Cell Biol. 2008, 10, 676–687.
100. Saitsu, H.; Nishimura, T.; Muramatsu, K.; Kodera, H.; Kumada, S.; Sugai, K.; Kasai-Yoshida, E.; Sawaura, N.; Nishida, H.; Hoshino, A. et al. De novo mutations in the autophagy gene WDR45 cause static encephalopathy of childhood with neurodegeneration in adulthood. Nat. Genet. 2013, 45, 445–449.
101. Cullup, T.; Kho, A.L.; Dionisi-Vici, C.; Brandmeier, B.; Smith, F.; Urry, Z.; Simpson, M.A.; Yau, S.; Bertini, E.; McClelland, V. et al. Recessive mutations in EPG5 cause vici syndrome, a multisystem disorder with defective autophagy. Nat. Genet. 2013, 45, 83–87.
102. Oz-Levi, D.; Ben-Zeev, B.; Ruzzo, E.K.; Hitomi, Y.; Gelman, A.; Pelak, K.; Anikster, Y.; Reznik-Wolf, H.; Bar-Joseph, I.; Olender, T. et al. Mutation in TECPR2 reveals a role for autophagy in hereditary spastic paraparesis. Am. J. Hum. Genet. 2012, 91, 1065–1072.
103. Lieberman, A.P.; Puertollano, R.; Raben, N.; Slaugenhaupt, S.; Walkley, S.U.; Ballabio, A. Autophagy in lysosomal storage disorders. Autophagy 2012, 8, 719–730.
104. Shimada, Y.; Klionsky, D.J. Autophagy contributes to lysosomal storage disorders. Autophagy 2012, 8, 715–716.
105. White, E. Deconvoluting the context-dependent role for autophagy in cancer. Nat. Rev. Cancer 2012, 12, 401–410.
106. Jiang, P.; Mizushima, N. Autophagy and human diseases. Cell Res. 2014, 24, 69–79.
107. Castedo, M.; Perfettini, J.L.; Roumier, T.; Valent, A.; Raslova, H.; Yakushijin, K.; Horne, D.; Feunteun, J.; Lenoir, G.; Medema, R. et al. Mitotic catastrophe constitutes a special case of apoptosis whose suppression entails aneuploidy. Oncogene 2004, 23, 4362–4370.
108. Denisenko, T.V.; Sorokina, I.V.; Gogvadze, V.; Zhivotovsky, B. Mitotic catastrophe and cancer drug resistance: A link that must to be broken. Drug Resist. Updates 2016, 24, 1–12.
109. Russell, P.; Nurse, P. CDC25+ functions as an inducer in the mitotic control of fission yeast. Cell 1986, 45, 145–153.
110. Molz, L.; Booher, R.; Young, P.; Beach, D. CDC2 and the regulation of mitosis: Six interacting mcs genes. Genetics 1989, 122, 773–782.
111. Ayscough, K.; Hayles, J.; MacNeill, S.A.; Nurse, P. Cold-sensitive mutants of p34CDC2 that suppress a mitotic catastrophe phenotype in fission yeast. Mol. Gen. Genet. 1992, 232, 344–350.
112. Nigg, E.A. Mitotic kinases as regulators of cell division and its checkpoints. Nat. Rev. Mol. Cell Biol. 2001, 2, 21–32.
113. Allan, L.A.; Clarke, P.R. Phosphorylation of caspase-9 by CDK1/cyclin B1 protects mitotic cells against apoptosis. Mol. Cell 2007, 26, 301–310.
114. Andersen, J.L.; Johnson, C.E.; Freel, C.D.; Parrish, A.B.; Day, J.L.; Buchakjian, M.R.; Nutt, L.K.; Thompson, J.W.; Moseley, M.A.; Kornbluth, S. Restraint of apoptosis during mitosis through interdomain phosphorylation of caspase-2. EMBO J. 2009, 28, 3216–3227.
115. Smits, V.A.; Medema, R.H. Checking out the G2/M transition. Biochim. Biophys. Acta 2001, 1519, 1–12.
116. Margottin-Goguet, F.; Hsu, J.Y.; Loktev, A.; Hsieh, H.M.; Reimann, J.D.; Jackson, P.K. Prophase destruction of Emi1 by the SCF(βTrCP/Slimb) ubiquitin ligase activates the anaphase promoting complex to allow progression beyond prometaphase. Dev. Cell 2003, 4, 813–826.
117. Yoshikawa, R.; Kusunoki, M.; Yanagi, H.; Noda, M.; Furuyama, J.I.; Yamamura, T.; Hashimoto-Tamaoki, T. Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: A novel target mechanism concept for pharmacokinetic modulating chemotherapy. Cancer Res. 2001, 61, 1029–1037.
118. Chan, T.A.; Hermeking, H.; Lengauer, C.; Kinzler, K.W.; Vogelstein, B. 14-3-3σ is required to prevent mitotic catastrophe after DNA damage. Nature 1999, 401, 616–620.
119. Vitale, I.; Galluzzi, L.; Castedo, M.; Kroemer, G. Mitotic catastrophe: A mechanism for avoiding genomic instability. Nat. Rev. Mol. Cell Biol. 2011, 12, 385–392.
120. Barrett, R.M.; Osborne, T.P.; Wheatley, S.P. Phosphorylation of survivin at threonine 34 inhibits its mitotic function and enhances its cytoprotective activity. Cell Cycle 2009, 8, 278–283.
121. Bunz, F.; Dutriaux, A.; Lengauer, C.; Waldman, T.; Zhou, S.; Brown, J.P.; Sedivy, J.M.; Kinzler, K.W.; Vogelstein, B. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998, 282, 1497–1501.
122. Chen, Z.; Xiao, Z.; Chen, J.; Ng, S.C.; Sowin, T.; Sham, H.; Rosenberg, S.; Fesik, S.; Zhang, H. Human Chk1 expression is dispensable for somatic cell death and critical for sustaining G2 DNA damage checkpoint. Mol. Cancer Ther. 2003, 2, 543–548.
123. Yun, J.; Chae, H.D.; Choy, H.E.; Chung, J.; Yoo, H.S.; Han, M.H.; Shin, D.Y. p53 negatively regulates CDC2 transcription via the CCAAT-binding NF-Y transcription factor. J. Biol. Chem. 1999, 274, 29677–29682.
124. Taylor, W.R.; DePrimo, S.E.; Agarwal, A.; Agarwal, M.L.; Schonthal, A.H.; Katula, K.S.; Stark, G.R. Mechanisms of G2 arrest in response to overexpression of p53. Mol. Biol. Cell 1999, 10, 3607–3622.
125. Taylor, W.R.; Stark, G.R. Regulation of the G2/M transition by p53. Oncogene 2001, 20, 1803–1815.
126. Goncalves, A.P.; Maximo, V.; Lima, J.; Singh, K.K.; Soares, P.; Videira, A. Involvement of p53 in cell death following cell cycle arrest and mitotic catastrophe induced by rotenone. Biochim. Biophys. Acta 2011, 1813, 492–499.
127. Ianzini, F.; Bertoldo, A.; Kosmacek, E.A.; Phillips, S.L.; Mackey, M.A. Lack of p53 function promotes radiation-induced mitotic catastrophe in mouse embryonic fibroblast cells. Cancer Cell Int. 2006, 6, 11.
128. Taylor, B.F.; McNeely, S.C.; Miller, H.L.; Lehmann, G.M.; McCabe, M.J., Jr.; States, J.C. p53 suppression of arsenite-induced mitotic catastrophe is mediated by p21CIP1/WAF1. J. Pharmacol. Exp. Ther. 2006, 318, 142–151.
129. Fragkos, M.; Beard, P. Mitotic catastrophe occurs in the absence of apoptosis in p53-null cells with a defective G1 checkpoint. PLoS ONE 2011, 6, e22946.
130. Mirza, A.; McGuirk, M.; Hockenberry, T.N.; Wu, Q.; Ashar, H.; Black, S.; Wen, S.F.; Wang, L.; Kirschmeier, P.; Bishop, W.R. et al. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 2002, 21, 2613–2622.
131. Jordan, M.A.; Wilson, L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer 2004, 4, 253–265.
132. Salmela, A.L.; Kallio, M.J. Mitosis as an anti-cancer drug target. Chromosoma 2013, 122, 431–449.
133. Mc Gee, M.M. Targeting the mitotic catastrophe signaling pathway in cancer. Mediat. Inflamm. 2015, 2015, 146282.
134. Sperandio, S.; de Belle, I.; Bredesen, D.E. An alternative, nonapoptotic form of programmed cell death. Proc. Natl. Acad. Sci. USA 2000, 97, 14376–14381.
135. Sperandio, S.; Poksay, K.; de Belle, I.; Lafuente, M.J.; Liu, B.; Nasir, J.; Bredesen, D.E. Paraptosis: Mediation by MAP kinases and inhibition by AIP-1/Alix. Cell Death Differ. 2004, 11, 1066–1075.
136. Lee, D.; Kim, I.Y.; Saha, S.; Choi, K.S. Paraptosis in the anti-cancer arsenal of natural products. Pharmacol. Ther. 2016, 162, 120–133.
137. Sugimori, N.; Espinoza, J.L.; Trung, L.Q.; Takami, A.; Kondo, Y.; An, D.T.; Sasaki, M.; Wakayama, T.; Nakao, S. Paraptosis cell death induction by the thiamine analog benfotiamine in leukemia cells. PLoS ONE 2015, 10, e0120709.
138. Li, B.; Zhao, J.; Wang, C.Z.; Searle, J.; He, T.C.; Yuan, C.S.; Du, W. Ginsenoside RH2 induces apoptosis and paraptosis-like cell death in colorectal cancer cells through activation of p53. Cancer Lett. 2011, 301, 185–192.
139. Pehar, M.; O’Riordan, K.J.; Burns-Cusato, M.; Andrzejewski, M.E.; del Alcazar, C.G.; Burger, C.; Scrable, H.; Puglielli, L. Altered longevity-assurance activity of p53:p44 in the mouse causes memory loss, neurodegeneration and premature death. Aging Cell 2010, 9, 174–190.
140. Neuberg, M.; Buckbinder, L.; Seizinger, B.; Kley, N. The p53/IGF-1 receptor axis in the regulation of programmed cell death. Endocrine 1997, 7, 107–109.
141. Ohlsson, C.; Kley, N.; Werner, H.; LeRoith, D. p53 regulates insulin-like growth factor-I (IGF-I) receptor expression and IGF-I-induced tyrosine phosphorylation in an osteosarcoma cell line: Interaction between p53 and Sp1. Endocrinology 1998, 139, 1101–1107.
142. Bergsbaken, T.; Fink, S.L.; Cookson, B.T. Pyroptosis: Host cell death and inflammation. Nat. Rev. Microbiol. 2009, 7, 99–109.
143. Miao, E.A.; Rajan, J.V.; Aderem, A. Caspase-1-induced pyroptotic cell death. Immunol. Rev. 2011, 243, 206–214.
144. Li, P.; Allen, H.; Banerjee, S.; Franklin, S.; Herzog, L.; Johnston, C.; McDowell, J.; Paskind, M.; Rodman, L.; Salfeld, J. et al. Mice deficient in IL-1β-converting enzyme are defective in production of mature IL-1β and resistant to endotoxic shock. Cell 1995, 80, 401–411.
145. Jorgensen, I.; Miao, E.A. Pyroptotic cell death defends against intracellular pathogens. Immunol. Rev. 2015, 265, 130–142.
146. Liu, X.; Zhang, Z.; Ruan, J.; Pan, Y.; Magupalli, V.G.; Wu, H.; Lieberman, J. Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores. Nature 2016, 535, 153–158.
147. Fink, S.L.; Cookson, B.T. Caspase-1-dependent pore formation during pyroptosis leads to osmotic lysis of infected host macrophages. Cell. Microbiol. 2006, 8, 1812–1825.
148. Hilbi, H.; Moss, J.E.; Hersh, D.; Chen, Y.; Arondel, J.; Banerjee, S.; Flavell, R.A.; Yuan, J.; Sansonetti, P.J.; Zychlinsky, A. Shigella-induced apoptosis is dependent on caspase-1 which binds to IPAB. J. Biol. Chem. 1998, 273, 32895–32900.
149. Gupta, S.; Radha, V.; Furukawa, Y.; Swarup, G. Direct transcriptional activation of human caspase-1 by tumor suppressor p53. J. Biol. Chem. 2001, 276, 10585–10588.
150. Kumar, S.; Birge, R.B. Efferocytosis. Curr. Biol. 2016, 26, R558–R559.
151. Sarode, G.S. Efferocytosis in oral squamous cell carcinoma. J. Oral Maxillofac. Pathol. 2016, 20, 170–172.
152. Stanford, J.C.; Young, C.; Hicks, D.; Owens, P.; Williams, A.; Vaught, D.B.; Morrison, M.M.; Lim, J.; Williams, M.; Brantley-Sieders, D.M. et al. Efferocytosis produces a prometastatic landscape during postpartum mammary gland involution. J. Clin. Investig. 2014, 124, 4737–4752.
153. Greenberg, M.E.; Sun, M.; Zhang, R.; Febbraio, M.; Silverstein, R.; Hazen, S.L. Oxidized phosphatidylserine-CD36 interactions play an essential role in macrophage-dependent phagocytosis of apoptotic cells. J. Exp. Med. 2006, 203, 2613–2625.
154. Parks, B.W.; Black, L.L.; Zimmerman, K.A.; Metz, A.E.; Steele, C.; Murphy-Ullrich, J.E.; Kabarowski, J.H. CD36, but not G2A, modulates efferocytosis, inflammation, and fibrosis following bleomycin-induced lung injury. J. Lipid Res. 2013, 54, 1114–1123.
155. McCubbrey, A.L.; Nelson, J.D.; Stolberg, V.R.; Blakely, P.K.; McCloskey, L.; Janssen, W.J.; Freeman, C.M.; Curtis, J.L. MicroRNA-34a negatively regulates efferocytosis by tissue macrophages in part via SIRT1. J. Immunol. 2016, 196, 1366–1375.
156. Raver-Shapira, N.; Marciano, E.; Meiri, E.; Spector, Y.; Rosenfeld, N.; Moskovits, N.; Bentwich, Z.; Oren, M. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol. Cell 2007, 26, 731–743.
157. Komarova, E.A.; Krivokrysenko, V.; Wang, K.; Neznanov, N.; Chernov, M.V.; Komarov, P.G.; Brennan, M.L.; Golovkina, T.V.; Rokhlin, O.W.; Kuprash, D.V. et al. p53 is a suppressor of inflammatory response in mice. FASEB J. 2005, 19, 1030–1032.